News Moderna drops mRNA jab for CMV after phase 3 fail Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital CMV infections, once touted as a future blockbuster.
R&D How a century-old technology could revolutionise LNP charact... The utility of AUC in LNP characterisation is growing, thanks to ongoing efforts to improve the technology.
News Moderna opens UK facility as drug pricing spat rumbles on The UK government has celebrated the opening of Moderna's £150m vaccines facility, but storm clouds continue to gather on the issue of drug pricing.
News GSK and CureVac settle mRNA patent spat with Pfizer/BioNTech BioNTech's takeover of CureVac seems to have unlocked a resolution to some of the patent litigation swirling around mRNA vaccine technologies.
News Pushback against Kennedy's mRNA decision builds The decision by HHS to cut funding for mRNA vaccines has caused dismay among scientists and public health experts, who have labelled it wrong-headed.
News RFK Jr cancels $500m in funding for mRNA vaccines RFK Jr is cutting $500m in funding for mRNA vaccines for diseases like flu and COVID-19, but critics say his reasons for doing so are spurious.
News Regenxbio, Solid report data with Duchenne gene therapies Regenxbio and Solid Bio say their gene therapies for Duchenne muscular dystrophy show no sign so far of the liver issues seen with Sarepta's Elevidys.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
